medline.ch Urologie-Nephrologie Tumoren BPH

tellmed.ch

medline.ch

En | De

Impressum | Feedback

Keine Artikel ausgewählt!

Warenkorb

Sie sind hier: Urologie-Nephrologie » Tumoren/BPH

21. Mai 2012

Kardiovaskuläre Erkrankungen

Muskuloskelettale Erkrankungen

Schrift:

Seite 1 von 4109


	Artikel 1 - 20 / 82168

	The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines. Cancer. Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB. PMID: 22605665 [PubMed - as supplied by publisher]
	Automatic segmentation of cell nuclei in Feulgen-stained histological sections of prostate cancer and quantitative evaluation of segmentation results. Cytometry A. Nielsen B, Albregtsen F, Danielsen HE. PMID: 22605528 [PubMed - as supplied by publisher]
	Current status of transrectal ultrasound techniques in prostate cancer. Curr Opin Urol. Smeenge M, de la Rosette JJ, Wijkstra H. PMID: 22595778 [PubMed - as supplied by publisher]
	Focal therapy in the management of prostate cancer: an emerging approach for localized prostate cancer. Adv Urol. Nomura T, Mimata H. PMID: 22593764 [PubMed - in process]
	Comparative Analysis of Sensitivity to Blood in the Urine for Urine-based Point-of-Care Assays (UBC rapid, NMP22 BladderChek and BTA-stat) in Primary Diagnosis of Bladder Carcinoma. Interference of Blood on the Results of Urine-based POC Tests. Anticancer Res. Lüdecke G, Pilatz A, Hauptmann A, Bschleipfer T, Weidner W. PMID: 22593481 [PubMed - in process]
	Serum amyloid a: a biomarker for renal cancer. Anticancer Res. Fischer K, Theil G, Hoda R, Fornara P. PMID: 22593464 [PubMed - in process]
	Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system. Am J Surg Pathol. Dong F, Wang C, Farris AB, Wu S, Lee H, Olumi AF, McDougal WS, Young RH, Wu CL. PMID: 22592143 [PubMed - in process]
	Comparative Effectiveness for Survival and Renal Function of Partial and Radical Nephrectomy for Localized Renal Tumors: A Systematic Review and Meta-Analysis. J Urol. Kim SP, Thompson RH, Boorjian SA, Weight CJ, Han LC, Murad MH, Shippee ND, Erwin PJ, Costello BA, Chow GK, Leibovich BC. PMID: 22591957 [PubMed - as supplied by publisher]
	Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. Urol Oncol. Abdollah F, Sun M, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Fossati N, Castiglione F, Freschi M, Karakiewicz P, Rigatti P, Montorsi F, Briganti A. PMID: 22591746 [PubMed - as supplied by publisher]
	Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res. Saylor PJ, Karoly ED, Smith MR. PMID: 22589396 [PubMed - as supplied by publisher]
	A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov. Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E, Nelson WG. PMID: 22586320 [PubMed - in process]
	A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. Am J Clin Pathol. Tradonsky A, Rubin T, Beck R, Ring B, Seitz R, Mair S. PMID: 22586051 [PubMed - in process]
	Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Non-Muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial. J Clin Oncol. Lammers RJ, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA. PMID: 22585689 [PubMed - as supplied by publisher]
	Metastatic Prostate Adenocarcinoma Diagnosed in a Colonic Polyp. J Clin Oncol. Steevens CD, Abraham J, Bahadur S. PMID: 22585688 [PubMed - as supplied by publisher]
	Is there any association between the severity of lower urinary tract symptoms and the risk of biopsy-detectable prostate cancer in patients with PSA level below 20?ng/ml in multi-core prostate biopsy? Prostate. Oh JJ, Jeong SJ, Jeong CW, Byun SS, Hong SK, Choe G, Lee SE. PMID: 22585359 [PubMed - as supplied by publisher]
	Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer. J Urol. Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW, Nathan FE, Higano CS. PMID: 22583636 [PubMed - as supplied by publisher]
	Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy. J Urol. Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M. PMID: 22583635 [PubMed - as supplied by publisher]
	Targeted therapy for advanced urothelial cancer of the bladder: Where do we stand? Anticancer Agents Med Chem. Zhu Z, Shen Z, Xu C. PMID: 22583418 [PubMed - as supplied by publisher]
	Personal hair dye use and the risk of bladder cancer: a case-control study from The Netherlands. Cancer Causes Control. Ros MM, Gago-Dominguez M, Aben KK, Bueno-de-Mesquita HB, Kampman E, Vermeulen SH, Kiemeney LA. PMID: 22581032 [PubMed - as supplied by publisher]
	Role of diffusion-weighted magnetic resonance imaging in prostate cancer evaluation. Radiol Med. Rinaldi D, Fiocchi F, Ligabue G, Bianchi G, Torricelli P. PMID: 22580813 [PubMed - as supplied by publisher]

Artikel 1 - 20 / 82168

Seite 1 von 4109



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch Tel: +41 (0)44 204 16 77 Fax: +41(0)44 204 16 70
	Disclaimer \| Privacy Policy